In the last week, the market has stayed flat, but it is up 20% over the past year, with earnings expected to grow by 18% per annum over the next few years. For those looking to invest in smaller or newer companies, penny stocks — despite being a somewhat outdated term — can still offer surprising value. In this article, we spotlight several penny stocks that stand out for their financial strength and potential for long-term success amidst current market conditions.

Below we spotlight a couple of our favorites from our exclusive screener.

SunCar Technology Group (SDA)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: SunCar Technology Group Inc. operates in the People's Republic of China, offering cloud and mobile app-based auto eInsurance, technology, and auto services through its subsidiaries, with a market cap of $91.81 million.

Operations: The company's revenue is derived from three main segments: Auto Service generating $230.65 million, Technology Service contributing $58.24 million, and Auto eInsurance Service bringing in $228.98 million.

Market Cap: $91.81M

SunCar Technology Group Inc. has secured a significant contract to manage auto insurance for Aistaland, a luxury EV brand co-developed by Huawei, reinforcing its position in the luxury EV market. Despite being unprofitable with increasing losses over the past five years, SunCar's revenue is projected to grow annually by 14.47%. The company maintains strong short-term asset coverage over liabilities and has reduced its debt-to-equity ratio from 143.6% to 89.6% in five years. However, it was recently dropped from the S&P Global BMI Index, highlighting volatility concerns despite positive cash flow growth and sufficient cash runway for three years.

SkinHealth Systems (SKIN)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: SkinHealth Systems Inc. is a global medical aesthetics company providing clinically proven solutions across various regions, with a market cap of $97.84 million.

Operations: The company generates $296.12 million in revenue from its Personal Products segment.

Market Cap: $97.84M

SkinHealth Systems Inc. recently received FDA clearance for its SkinStylus microneedling device, expanding its market potential in the medical aesthetics sector. Despite generating US$296.12 million in revenue, the company faces challenges with a high net debt-to-equity ratio of 256.8% and non-compliance with Nasdaq's minimum bid price requirement, risking delisting if not addressed by November 2026. While unprofitable and experiencing share price volatility, SkinHealth has reduced losses annually by 46.4% over five years and maintains a strong cash runway exceeding three years due to positive free cash flow growth of 41.7%.

Tvardi Therapeutics (TVRD)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapies targeting STAT3 for treating inflammatory and proliferative diseases with significant unmet needs in the United States, with a market cap of $29.08 million.

Operations: Tvardi Therapeutics, Inc. has not reported any revenue segments.

Market Cap: $29.08M

Tvardi Therapeutics is a pre-revenue company with a market cap of US$29.08 million, focusing on innovative therapies targeting STAT3 for inflammatory and proliferative diseases. Despite being unprofitable and experiencing significant share price volatility, Tvardi's recent Phase 1 study of TTI-109 demonstrated promising pharmacokinetics and target engagement, potentially enhancing its therapeutic profile over existing treatments. The company maintains strong financial health with short-term assets exceeding liabilities and no debt, supported by a cash runway extending over a year. However, future progress hinges on securing additional funding following recent equity offerings totaling $12.5 million.

Make It Happen

• Investigate our full lineup of 325 US Penny Stocks right here.
• Curious About Other Options? AI is about to change healthcare. These 131 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.